Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study

Lorlatinib significantly improved progression-free survival (PFS) versus crizotinib and showed robust intracranial activity in patients with previously untreated advanced ALK-positive non–small-cell lung cancer (NSCLC) in the phase III CROWN trial. Here, we report post hoc efficacy outcomes in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomon, Benjamin J., Bauer, Todd M., Ignatius Ou, Sai-Hong, Liu, Geoffrey, Hayashi, Hidetoshi, Bearz, Alessandra, Penkov, Konstantin, Wu, Yi-Long, Arrieta, Oscar, Jassem, Jacek, Calella, Anna M., Peltz, Gerson, Polli, Anna, Thurm, Holger, Mok, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622589/
https://www.ncbi.nlm.nih.gov/pubmed/35605188
http://dx.doi.org/10.1200/JCO.21.02278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622589/
https://www.ncbi.nlm.nih.gov/pubmed/35605188
http://dx.doi.org/10.1200/JCO.21.02278

Ejemplares similares